Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
SRK Capital Sean Kirkwood | “Sanuwave Health, Inc. ($SNWV) develops and commercializes patented non-invasive biological response activating medical systems, primarily its UltraMist acoustic wave therapy platform used in wound-care clinics. The fund fully liquidated its remaining position in the first half of 2026, transitioning to a bearish stance due to a breakdown in end-customer economics and deteriorated visibility into future platform demand. The unit economics of Sanuwave's primary distribution channel have deteriorated sharply. Recent top-line growth had been propelled by mobile wound-care operators that historically enjoyed elevated profit margins by administering tissue-based skin grafts. However, as healthcare payors increased reimbursement scrutiny and reduced fee schedules, these clinic operators experienced severe cash flow compression. Because UltraMist does not enjoy similar high-margin reimbursement characteristics, financially strained mobile clinics face elevated insolvency risks, directly impairing Sanuwave's sales pipeline. The manager concluded that the risk/reward profile is no longer favorable, opting to reallocate capital into businesses with higher cash flow predictability. Going forward, the primary risk for Sanuwave is substantial customer churn and revenue contraction within its core distribution network as clinics restructure or fail.” | BEAR | Q2 2026 Aug 1, 2026 | View Pitch |
Far View Capital Management Brad Hathaway | “Offsetting these solid results, Far View suffered substantial losses in Sanuwave (SNWV). Continued disruption in the wound-care market stemming from CMS audits contributed to practitioner bankruptcies and the emergence of an unauthorized gray market for used Ultramist devices. As a result, the company was forced to cut guidance in H1 2026. This guidance cut could not have come at a worse time because the company was also scheduled to be removed from the Russell 2000 at the end of June 2026, adding significant passive selling pressure to a stock undergoing a fundamental disruption. While these industry challenges had a larger impact on near-term results than I anticipated, I remain optimistic that Sanuwave's attractive, evidence-based Ultramist system is well positioned to substantially expand its footprint over the mid-term, which should produce highly attractive economics for its machine and consumables model. As a result, we added to our position in late June.” | NEUTRAL | Q2 2026 Jul 17, 2026 | View Pitch |
Cedar Grove Capital Management Paul Cerro | “Our biggest detractors were KITS Eyewear (KITS.TO), Sanuwave Health (SNWV), and Evolv Technologies (EVLV). Sanuwave was a position that we first highlighted almost a year ago, and we were bullish on the long-term prospects of the company in the wound care space. While we knew that changes to overall wound care reimbursement were coming from the Centers for Medicare and Medicaid Services (CMS), we felt confident that their main device, the UltraMist, would come out unscathed. This turned out to be true, but unfortunately, the damage done to the overall market (clinics, centers, mobile care, etc.) effectively made Sanuwave collateral damage above and beyond what any long investor had thought. First occurring in Q4'25, it spilled into 2026 and led to Sanuwave having to lower Q2'26 guidance dramatically on the device front. The stock dropped ~40% that day, and while we are bullish on the device and the space, it's clear that not many people know exactly where the bottom is. We decided to exit the position to secure a tax loss but would still like to keep an eye on the company and the space if/should evidence arise that the wound care tides are turning once again. This position had a large negative impact on the quarter's performance due to the surprising guidance cut in mid-June.” | NEUTRAL | Q2 2026 Jul 15, 2026 | View Pitch |
“Sanuwave health (SNWV) is a specialty medical device company with an incredible opportunity in front of it. Sanuwave is the maker and distributor of UltraMist, a low-frequency, non-contact ultrasound energy device that delivers wound care treatment through a fluid mist. UltraMist is FDA approved and reimbursed through Nationwide CMS reimbursement via a therapy specific CPT code. The investment thesis for Sanuwave Health, Inc. centers on a fundamental shift in the advanced wound care ecosystem, transitioning from high-cost, under-regulated biological grafts toward energy-based tissue regeneration. As the medical community and federal payers grapple with a multi-billion dollar surge in unsustainable spending on skin substitutes, Sanuwave has positioned its directed energy platforms with UltraMIST as a high-value alternative. Sanuwave utilizes a "razor blade" recurring revenue model that has achieved record quarterly revenues throughout 2025, culminating in a preliminary full-year revenue projection of $44.3 million to $44.4 million (36% y-o-y increase). This growth is underpinned by the UltraMIST system, which provides non-contact, low-frequency ultrasound to stimulate cellular-level healing. The DermaPACE system, the first shockwave therapy to receive FDA clearance for diabetic foot ulcers (DFUs), is also a part of the product portfolio but is not a major driver in the company's growth. The management team and company were recently restructured under CEO Morgan Frank. Morgan is a hedge fund guy, who has run the Manchester Explorer Fund for the last 23 years. Morgan spent the last few years building a sales and operating team with veterans from high-growth medical technology firms like Abiomed and Healogics. In late 2024 the company successfully transformed the company's capital structure through a warrant conversion and reverse stock split. Then in 2025 the company refinanced its debt with JPMorgan Chase eliminated legacy high-interest debt, reducing the cost of capital and providing the liquidity necessary for commercial scaling. All of these actions have set the company up for a multi year path of growth with a high free cashflow conversion. The competitive landscape is currently undergoing a significant disruption due to the Centers for Medicare & Medicaid Services (CMS) final rule for 2026. This regulation reduces Medicare spending on skin substitutes by approximately 90%, or $19.6 billion, by reclassifying them as "incident-to" supplies and imposing a flat reimbursement rate. This change caused much uncertainty in 2025 in the market, as users of all wound care products shifted their buying patterns to adjust for the change. But over the long term I view the changes as positive for Sanuwave, as biological competitors struggle with the reimbursement changes Sanuwave's UltraMIST product will maintain a stable and preferred reimbursement profile under CPT code 97610. With an addressable market for advanced wound care projected to reach $17.8 billion by 2033 and a business model producing 78% gross margins, Sanuwave represents a compelling asymmetric opportunity for investors. BSD Analysis: Sanuwave represents a classic small-cap med-tech inflection story driven by regulatory change, operational restructuring, and accelerating fundamentals. The company is transitioning from subscale execution to institutional-grade operations, with revenue growth of 60% in 2024 and 36% in 2025 and gross margins approaching 78%. CMS reimbursement reform is a powerful external catalyst, effectively dismantling biological graft competitors while reinforcing UltraMIST's preferred CPT reimbursement. At ~5.6x sales and ~15x forward EV/EBITDA, the stock trades at a discount to peers despite superior growth and margin profile. Balance sheet risk has been materially reduced through refinancing, and operating leverage should drive rapid EBITDA expansion. If execution continues, multiple expansion toward 25–30x EBITDA is plausible, supporting a compelling upside skew.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch | |
SRK Capital Sean Kirkwood | “Sanuwave continues on with the theme of rapid growth and an imminent Nasdaq uplisting. In March, SNWV announced its uplisting to the Nasdaq and was added to the Russell 2000 index at the end of June. For the first half of the year, Sanuwave has grown revenue 51%. Even more impressive, this growth was achieved without a national sales presence. Following the first half of the year, the company now has a national sales force along with a key account manager focused on pursuing large accounts that have several hundred locations across the country. Management reaffirmed guidance for the year, which appears to be on the conservative side as it doesn't include the potential for any new large accounts. Additionally, management indicated that they have been pursuing options to refinance their debt and have received several options with very attractive terms, removing the fear of a potential equity offering. With a large account manager and their first ever targeted outbound marketing campaign I expect Sanuwave to continue to execute. Gross margins should continue to expand beyond the current 78% through manufacturing improvements. Shares continue to represent an attractive investment as the company trades at a discount to similar medical device companies with less attractive growth prospects. BSD Analysis: Sanuwave is a micro-cap medtech-style story where the entire investment case typically hinges on clinical validation, commercialization execution, and funding runway. If the technology improves outcomes and reimbursement is achievable, upside can be large because small starting revenue bases scale fast. The downside is dilution risk and long sales cycles—hospitals and clinics don't adopt new devices quickly without clear economic proof. Investors should watch regulatory status, payer coverage progress, and whether repeat usage is growing, not just headline announcements. Manufacturing, distribution, and clinician training can become hidden execution traps. This is not a “steady compounder” setup; it's a high-variance adoption and financing story. Position sizing matters more than conviction here.” | BULL | Q2 2025 Aug 1, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
